SGLT2 Inhibitors role in Heart Failure: More Than Just Glycemic Control
DOI:
https://doi.org/10.63501/zqz05q25Abstract
Not applicable
References
1. Darwish D, Kumar P, Urs K, Dave S. Impact of SGLT-2 Inhibitors on Biomarkers of Heart Failure. Cells. 2025;14(12):919. doi:10.3390/cells14120919.
2. Rauf U, Ansar F, Ali MS, Chudhary F, Zafar MH, Azzam A, et al. Effect of Empagliflozin on Cardiovascular Mortality and Heart Failure Hospitalizations: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cureus. 2025;17(6):e85669. doi:10.7759/cureus.85669.
3. Albulushi A, Askari KM, Al-Abedi AM, et al. Impact of SGLT2 inhibitors on myocardial fibrosis in diabetic HFpEF: a longitudinal study. Eur J Med Res. 2025;30(1):592. doi:10.1186/s40001-025-02834-7.
4. Li J, Wang X, Zheng Q, Tian J, Chen H, Yao S. Effects of SGLT2 inhibitors on cognitive impairment in elderly inpatients with heart failure with reduced ejection fraction: a prospective cohort study. BMC Cardiovasc Disord. 2025;25(1):485. doi:10.1186/s12872-025-04952-w.
5. Santos Guzmán MV, Rivera D, Reyna Guerrero IM, et al. Efficacy of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors in Heart Failure With Preserved Ejection Fraction: A Systematic Review. Cureus. 2025;17(5):e84129.